Transcriptomics

Dataset Information

0

Chronic ISG15 Exposure Accelerates CD8 T Cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma


ABSTRACT: Immunotherapy has emerged as a promising treatment for head and neck squamous cell carcinoma (HNSCC), but clinical responses remain limited. Elevated expression of interferon-stimulated gene 15 (ISG15), associated with oral squamous cell carcinoma (OSCC), may contribute to this limited efficacy. While chronic interferon signaling impairs CD8 T cell function, the specific role of secreted ISG15 in T cell exhaustion remains unclear. Analyzing human OSCC datasets, we observed significant enrichment of the ISG core score, including ISG15, in tumors compared to adjacent non-tumor tissues. Using a novel in vitro model of human T cell dysfunction, we found that acute ISG15 exposure enhances CD8 T cell effector functions, whereas prolonged ISG15 exposure induces severe dysfunction via an endocytic mechanism independent of LFA-1 signaling. In an immunocompetent orthotopic OSCC model, ISG15-expressing tumors exhibited accelerated growth and recruited more tumor-reactive CD8 T cells though these cells were dysfunctional. Importantly, PD-1 blockade treatment significantly slowed tumor progression and restored T cell functionality in ISG15-expressing tumors. Our findings indicate that chronic ISG15 exposure promotes CD8 T cell dysfunction; however, these cells remain responsive to PD-1 blockade. This study reveals ISG15 as a potential biomarker for identifying patients likely to benefit from PD-1 blockade therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE297506 | GEO | 2025/08/10

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA1265105 | ENA
2023-06-16 | MSV000092193 | MassIVE
2016-08-02 | E-GEOD-84105 | biostudies-arrayexpress
2025-07-07 | GSE288889 | GEO
2016-07-01 | E-GEOD-73001 | biostudies-arrayexpress
2011-01-11 | E-GEOD-26495 | biostudies-arrayexpress
2023-06-16 | GSE206325 | GEO
2020-05-01 | GSE145896 | GEO
2023-04-19 | PXD040957 | Pride
2024-01-16 | MTBLS5358 | MetaboLights